Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Kevin Bowrin"'
Autor:
Csaba Kovesdy, Niklas Schmedt, Kerstin Folkerts, Kevin Bowrin, Hanaya Raad, Michael Batech, Linda Fried
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-15 (2022)
Abstract Background Clinical practice guidelines recommend sodium-glucose co-transporter 2 inhibitors (SGLT2is) to mitigate adverse kidney and cardiovascular outcomes in patients with type 2 diabetes (T2D), including patients with comorbid chronic ki
Externí odkaz:
https://doaj.org/article/0aaecc53db484759afc7801ab51ac811
Autor:
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0266658 (2022)
AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients wi
Externí odkaz:
https://doaj.org/article/eb092c35bbd84ed6aa5885bab357e8be
Autor:
Olivia Wu, Stephen Morris, Torben Bjerregaard Larsen, Flemming Skjøth, Alex Evans, Kevin Bowrin, Piotr Wojciechowski, Wojciech Margas, Maria Huelsebeck
Publikováno v:
Cardiovascular Therapeutics, Vol 2022 (2022)
Background. Rivaroxaban and apixaban are the most widely used nonvitamin K oral anticoagulants (NOACs) in patients with venous thromboembolism (VTE). This meta-analysis evaluates the effectiveness and safety of both NOACs versus standard of care (SoC
Externí odkaz:
https://doaj.org/article/b82b86ef066647978671c433fa67a737
Autor:
Rupert Bauersachs, Olivia Wu, Neil Hawkins, Kevin Bowrin, Piotr Wojciechowski, Emilie Clay, Maria Huelsebeck
Publikováno v:
Cardiovascular Therapeutics, Vol 2021 (2021)
Background. The guidelines on antithrombotic treatment in patients with symptomatic peripheral artery disease (PAD) undergoing peripheral revascularization of the lower extremities were developed based on heterogeneous trials, assessing various dose
Externí odkaz:
https://doaj.org/article/ed4f966f29ea426191aa307c4490e39d
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system. Objectives An existing Markov model was adapted to assess the real-world cost-effectiveness
Externí odkaz:
https://doaj.org/article/5e95112410e74f1183cf795e93f044e3
Autor:
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, Mondher Toumi, Emilie Clay, Pierre Levy
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0225301 (2020)
OBJECTIVE:The objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation (AF) from a French national health insurance perspective. METHODS:
Externí odkaz:
https://doaj.org/article/8513bdea822c4f258201969642d1647f
Autor:
Rupert Bauersachs, Olivia Wu, Jean-Baptiste Briere, Kevin Bowrin, Katarzyna Borkowska, Anna Jakubowska, Vanessa Taieb, Mondher Toumi, Maria Huelsebeck
Publikováno v:
Cardiovascular Therapeutics, Vol 2020 (2020)
Aims. Acetylsalicylic acid (ASA) is widely used for the prevention of atherothrombotic events in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD), but the risk of vascular events remains high. We aimed at identi
Externí odkaz:
https://doaj.org/article/0e9c997f5b3640919ca68eb1c4468e08
Autor:
Rupert Bauersachs, Uwe Zeymer, Jean-Baptiste Brière, Caroline Marre, Kevin Bowrin, Maria Huelsebeck
Publikováno v:
Cardiovascular Therapeutics, Vol 2019 (2019)
Background. Atherothrombotic disease, including coronary artery disease (CAD) and peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial infarction, stroke, limb ischemia, heart failure, and CV death. Aim. Evaluat
Externí odkaz:
https://doaj.org/article/78312963b30e47649bbc3d4ae543ad1c
Autor:
Craig I. Coleman, Jean-Baptiste Briere, Laurent Fauchier, Pierre Levy, Kevin Bowrin, Mondher Toumi, Aurélie Millier, Vanessa Taieb, Olivia Wu
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF). A meta-analysis was performed to synthesize the a
Externí odkaz:
https://doaj.org/article/2a8f043b0a824dbaa571cb468c552b94
Autor:
Pierre Levy, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin, Jean-Baptiste Briere
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France. Objectives: To evaluate monthly per-patient costs attributable to VKA treatment in NV
Externí odkaz:
https://doaj.org/article/36db1862bbdc4647977d929223085b73